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in all genotypes (~30% in African Americans). Alinia
(nitazoxanide[NTZ]), an interferon inducer may increase
SVR in combination with PegIFN and RBV. Very rapid virologic
response (VRVR) deﬁned as undetectable HCVRNA 14 days
after initiation of combination therapy may predict even
higher SVR rates. We assessed NTZ in combination with
high-dose RBV and PegIFN alfa-2a in Hepatitis C treatment.
Methods: Prospective, open-label, pilot study of naı¨ve
patients with chronic hepatitis C GT1. 33 patients
were enrolled. Exclusions: uncontrolled diabetes mellitus,
decompensated cirrhosis etc. Patients received NTZ 500mg
bid for ﬁrst 2 weeks; RBV 800mg in AM and 600mg at night
added to NTZ for next 2 weeks; subcutaneous PegIFN alfa-2a
180mcg weekly added to RBV and NTZ at the same dose
(triple-regimen) for next 12 weeks. Patients who achieved
EVR continued PegIFN alfa-2a and RBV for the next 36 weeks
at the same dose. VRVR, Rapid Viral Response (RVR), Early
Viral response (EVR), End Treament Viral Response (ETR),
and Sustained Viral Response (SVR) were assessed (COBAS
TaqMan HCV Test v2.0, Roche Diagnostics).
Results: Overall SVR 66.7% (22/33). Demographics:
Caucasian (n = 16, 48.5%), Hispanic (n = 6, 18.2%), African-
American (n = 5, 15.1%), and Asian (n = 6, 18.2%). Mean
BMI 27.9; mean HCVRNA-600,000 IU/ml; ﬁbrosis score-
F2 (48.5%). Growth factors were used to minimize
dose reductions. Adverse effects (AE): skin rash (27.3%);
neutropenia (51.5%); thrombocytopenia (39.4%); anemia
(48.5%); 6.1% discontinued treatment due to AE. None had
dose reductions.
Conclusion: This regimen of NTZ, high-dose RBV and PegIFN
alfa-2a enhances RVR over historical controls and offers an
improved SVR rate of 66.7% compared to 40.9% SVR rate in
GT1 from the recent IDEAL Study.
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To promote the diagnostic rate of HIV/AIDS complicated with
cytomegalovirus (CMV) viremia, enhance curative effects
and improve the prognosis. The clinical data in 249 cases of
HIV/AIDS patients hospitalized from Oct.2008 to Nov. 2009
have been collected and studied retrospectively, in which
we found that 43 HIV/AIDS patients have infected CMV.
Pathological detections have been analyzed from specimen
taken with gastroscope, ﬁbercoloscope, bronchoscope and
bronchoalveolar lavage ﬂuid (BALF). We also analyzed
association between cellular immunity and CMV-DNA levels.
We found that 43 patients (17.3%) have been diagnosed
as CMV viremia in accordance with positive results of
CMV pp65 antigen and CMV-DNA; 14 patients manifested
Figure 1. Retinitis.
Figure 2. CMV pneumonitis.
retinal bleeding or inﬁltration and 4 patients displayed
retinal ﬁbrosis; 1 patients have been diagnosed as CMV
pneumonitis according to pathological results from BALF;
No CMV esophagitis or colitis has been diagnosed in
these 43 patients. We also found the positive association
between low level of CD4+T lymphocytes and CMV-DNA
levels. The detections of CMV pp65 antigen and CMV-
DNA should be detected and anti-CMV treatment should
be taken in HIV/AIDS patients with less than 50/ul
of CD4+T lymphocytes. Ophthalmologic examination and
pathological detection in BALF are effective methods in
diagnosing CMV retinitis and pneumonitis.
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Background: HIV-1 genotypic-resistance is becoming
increasingly signiﬁcant in drug resistance monitoring.
However, many areas in some developing countries in Asia
still lack of such information due to its high running cost.
This is the ﬁrst study to determine the prevalence of
drug resistance mutations of reverse transcriptase (RT) and
protease (PR) genes and speciﬁc HIV-1 subtypes in North-
eastern part of Malaysia.
Methods: The genotypic resistance testing was performed
among 50 HIV-1 seropositive treated and treatment naı¨ve
subjects in Hospital Raja Perempuan Zainab 2, Kota Bharu.
The HIV-1 PR and RT genes were ampliﬁed from 140ml of
plasma-derived HIV-1 viral RNA via reverse transcription-
polymerase chain reaction and genotype determined via
DNA sequencing. Drug resistance mutations were analysed
using the Stanford HIV Sequence Resistance Database.
Results: CRF01_AE was found to be the dominant subtype
by both PR and RT genes in both antiretroviral treated and
naive patients (59.4%). B subtype was present to a much
lower level (21.9%), followed by CRF01_AE/B intersubtype
recombinant (18.8%). Fifteen percent of the treated and
0.06% naı¨ve patients had mutations associated with PIs.
The frequency of mutations associated with NRTIs and
NNRTIs resistance in treated patients was 40.6% and 34.4%,
respectively compared to 0.06% and 0.09% in naı¨ve patients.
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M184V and K103N mutations were being selected most
frequently by these drugs. The pattern of prevalence of
ARV-resistant HIV-1 variants was NRTI-resistant > NNRTI-
resistant > PI-resistant.
Conclusions: The prevalence of major drug resistance
mutations among HIV patients with detectable viral load
is high in Kelantan.
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Background: HIV-1 virion infectivity factor (vif) inactivates
host cytidine deaminases hAPOBEC3G, hAPOBEC3B and
hAPOBEC3F during the viral life cycle.
Methods: Because of this critical role of vif, analyzing its
diversity and exploring its conserved regions is of primary
importance. In this study, we expressed vif and hA3G/B/F
in serum and PBMCs of HIV-1 infected individuals in vitro.
Result: A signiﬁcantly high level of polymorphism was
present in vif gene, and some general characteristics
were observed in corresponding amino acid sequences.
In addition, neutralization of the in vitro recombinant vif
protein reduced markedly to antibodies of blood from the
HIV-1 infected individuals. It was indicated that increased
levels of hA3G/B/F mRNA in HIV-1 infected individuals did
not contribute to the progression of disease in the late stage
of the viral disease. The results suggested that the diversity
of vif gene in HIV-1 strain from the Shanghai area, China
has unique characteristics.
Conclusion: There is a conserved region in vif as a reliable
drug target for further study. hA3G/B/F expression is
correlated with progression of HIV disease except in the
late stage of this viral disease.
The ﬁrst three authors’ contributions to this study were
equal.
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Background: Group A coxsackievirus type 16 (CA16) and
enterovirus type 71 (EV71) are the most commonly isolated
from HFMD cases. 1,155,603 cases were reported in China
mainland in 2009, in which severe disease were 14,214
and the fatal case were 354. Among these fatal patients,
children under 5 years of age was estimated 93.09%.
Researching and developing the EV71 vaccine is the only
way to control HFMD.
Methods: Viral complete sequence was obtained by RT-PCR
and 5′, 3′ rapid ampliﬁcation of cDNA ends (RACE). The
nucleotide identity between sequences was calculated and
sequence alignments were made to generate phylogenetic
trees using MegAlign in DNAStar. The complete genome was
cloned into pGEM-9zf( ) vector.
Result: 2 strains of EV71 (BJ08, R20) and 1 strain of
CA16 (BJCA08) from Beijing were cultured and isolated
in Vero cells. Viral RNA was detected by RT-PCR and
complete sequence was obtained from the 3 strains.
Phylogenetic analysis indicated that BJ08, R20 belonged
to C4 subtype and BJCA08 belong to C1 subtype. The
ampliﬁcation assay for the complete genome of EV71 was
preliminary established. The complete genome of 8 EV71
strains, including BJ08, R20 and 6 vaccine strains from
manufacturers, were obtained. Sequences analysis showed
that all 6 vaccine strains belong to C4 subtype. An infectious
cDNA clone of EV71 (BJ08) had been constructed. Further
studies on the EV71 cDNA clone was carried out in near
future, which may help us to study the relationship between
structure and function of EV71.
Conclusion: C4 subtype was predominated in epidemiology
of EV71 in China mainland. Compare with EV71, the data
of CA16 is much less and a few data indicated that B
subtype and C subtype co-circulate in China mainland. More
EV71/CA16 information of etiology and epidemiology are
needed for researching and development and quality control
EV71 vaccine.
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Background: EV71 is the commonest etiological agent
isolated from the HFMD patients. Little information is
available on the evolution of EV71 in mainland China and
genetic basis for different symptoms. No effective vaccines
against this virus are available.
Methods:
1. The phylogenetic tree of the 61 typical EV71 strains was
constructed. Whole nucleotide and amino acid sequences
of the Foshan308 (FJ194964), Shaoguan08 (FJ194965),
Zhej08 (EU864507) and Shzh03 (AY465356) resulting in
different clinical outcomes were comparably analyzed.
2. Transform P1-pGAPZa-A and 3CD-pGAPZa-A recombinant
plasmids into SMD1168 and get the recombinant
expression strain expressing P1 and 3CD proteins.
Visualize the VLPs by electronmicroscope. Animal
experiments were carried out to evaluate the immune
effect of EV71 VLPs vaccine.
Results:
1. Since 2002, a new C6 subgenotype has been formed.
2. Strains isolates in 2008 mutated in amino acid positions
91, 93, 94, 95, 96, 945, 1140, 1148, 1426, 1534, 1541,
1597, 1807, 1820, 1928, 2101, 2125, 2156 and 2158.
Special variants occurred in nucleotide positions 90,
187, 291, 385, 497, 601, 664, 681, 704, 705 at 5′ UTR
and 42, 56, 74 at 3′UTR, as well as amino acid positions
854, 891, 964, 1108, 1422, 1641, 1776, 1874, 1921, 1982,
1992 and 2173 in Foshan308 fatal strain.
3. P1-pGAPZa-A and 3CD-pGAPZa-A recombinant plasmids
were constructed and transformed into SMD1168
simultaneously. EV71 VLPs constructed and can elicit
immune response on animals.
Conclusions:
1. A new C6 subgenotype contributed to the EV71 large
outbreak in mainland China from 2007 to 2009.
2. Amino acid mutations of strains isolated in 2008 were
related to the large-scale outbreak in 2008. Special
mutations of Foshan308 were relevant to virulence.
